130 related articles for article (PubMed ID: 37182841)
41. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
[TBL] [Abstract][Full Text] [Related]
42. Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections.
Pedersen RM; Bang LL; Tornby DS; Madsen LW; Holm DK; Sydenham TV; Johansen IS; Jensen TG; Justesen US; Andersen TE
Emerg Infect Dis; 2022 Dec; 28(12):2575-2577. PubMed ID: 36347270
[TBL] [Abstract][Full Text] [Related]
43. Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial.
Xu PP; Fu D; Li JY; Hu JD; Wang X; Zhou JF; Yu H; Zhao X; Huang YH; Jiang L; Liu F; Su LP; Chen ZW; Zeng QS; Chen JP; Fang MY; Ma J; Liu T; Song YP; Yu K; Li Y; Qiu LG; Chen XQ; Gu J; Yan JS; Hou M; Huang HY; Wang L; Cheng S; Shen Y; Xiong H; Chen SJ; Zhao WL
Lancet Haematol; 2019 Jun; 6(6):e328-e337. PubMed ID: 31126528
[TBL] [Abstract][Full Text] [Related]
44. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
45. 3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis.
Araie H; Sakamaki I; Matsuda Y; Tai K; Ikegaya S; Itoh K; Kishi S; Oiwa K; Okura M; Tasaki T; Hosono N; Ueda T; Yamauchi T
Intern Med; 2017 Sep; 56(18):2407-2413. PubMed ID: 28824057
[TBL] [Abstract][Full Text] [Related]
46. SARS-CoV-2 shedding and seroconversion among passengers quarantined after disembarking a cruise ship: a case series.
Hung IF; Cheng VC; Li X; Tam AR; Hung DL; Chiu KH; Yip CC; Cai JP; Ho DT; Wong SC; Leung SS; Chu MY; Tang MO; Chen JH; Poon RW; Fung AY; Zhang RR; Yan EY; Chen LL; Choi CY; Leung KH; Chung TW; Lam SH; Lam TP; Chan JF; Chan KH; Wu TC; Ho PL; Chan JW; Lau CS; To KK; Yuen KY
Lancet Infect Dis; 2020 Sep; 20(9):1051-1060. PubMed ID: 32539986
[TBL] [Abstract][Full Text] [Related]
47. Booster Dose of SARS-CoV-2 mRNA Vaccine in Kidney Transplanted Patients Induces Wuhan-Hu-1 Specific Neutralizing Antibodies and T Cell Activation but Lower Response against Omicron Variant.
Del Mastro A; Picascia S; D'Apice L; Trovato M; Barba P; Di Biase I; Di Biase S; Laccetti M; Belli A; Amato G; Di Muro P; Credendino O; Picardi A; De Berardinis P; Del Pozzo G; Gianfrani C
Viruses; 2023 May; 15(5):. PubMed ID: 37243218
[TBL] [Abstract][Full Text] [Related]
48. Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals.
Kuzel TG; Fu J; Anderson M; Stec M; Boler M; Behun D; Gosha A; Cloherty G; Landay A; Moy J
Vaccine; 2023 Jan; 41(4):879-882. PubMed ID: 36572601
[TBL] [Abstract][Full Text] [Related]
49. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
[TBL] [Abstract][Full Text] [Related]
50. T Cell Response following Anti-COVID-19 BNT162b2 Vaccination Is Maintained against the SARS-CoV-2 Omicron B.1.1.529 Variant of Concern.
Cohen H; Rotem S; Elia U; Bilinsky G; Levy I; Chitlaru T; Bar-Haim E
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215940
[TBL] [Abstract][Full Text] [Related]
51. Managing the front-line treatment for diffuse large B cell lymphoma and high-grade B cell lymphoma during the COVID-19 outbreak.
de la Cruz-Benito B; Lázaro-Del Campo P; Ramírez-López A; de Soto-Álvarez T; Sánchez-Vadillo I; García-Pérez E; Dos Santos-Ortas A; Humala-Barbier K; López-de la Guía A; Casado-Abad G; Jiménez-Yuste V; Canales-Albendea M
Br J Haematol; 2020 Nov; 191(3):386-389. PubMed ID: 32762043
[TBL] [Abstract][Full Text] [Related]
52. Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after third-dose BNT162b2 in adolescents.
Mu X; Cohen CA; Leung D; Rosa Duque JS; Cheng SMS; Chung Y; Wong HHW; Lee AMT; Li WY; Tam IYS; Lam JHY; Lee DHL; Chan SM; Tsang LCH; Chan KCK; Li JKC; Luk LLH; Chaothai S; Kwan KKH; Chu NC; Mori M; Jeevan T; Kandeil A; Webby RJ; Tu W; Valkenburg SA; Peiris M; Lau YL
Signal Transduct Target Ther; 2022 Dec; 7(1):397. PubMed ID: 36517469
[TBL] [Abstract][Full Text] [Related]
53. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
[TBL] [Abstract][Full Text] [Related]
54. Clinical characteristics of healthcare workers with SARS-CoV-2 infection after vaccination with BNT162b2 vaccine.
Lombardi A; Renisi G; Consonni D; Oggioni M; Bono P; Uceda Renteria S; Piatti A; Pesatori AC; Castaldi S; Muscatello A; Riboldi L; Ceriotti F; Gori A; Bandera A
BMC Infect Dis; 2022 Jan; 22(1):97. PubMed ID: 35090388
[TBL] [Abstract][Full Text] [Related]
55. SARS-CoV-2 live virus neutralization after four COVID-19 vaccine doses in people with HIV receiving suppressive antiretroviral therapy.
Cheung PK; Lapointe HR; Sang Y; Ennis S; Mwimanzi F; Speckmaier S; Barad E; Dong W; Liang R; Simons J; Lowe CF; Romney MG; Brumme CJ; Niikura M; Brockman MA; Brumme ZL;
AIDS; 2023 Apr; 37(5):F11-F18. PubMed ID: 36789806
[TBL] [Abstract][Full Text] [Related]
56. Factors associated with prolonged viral shedding in older patients infected with Omicron BA.2.2.
Zhong W; Yang X; Jiang X; Duan Z; Wang W; Sun Z; Chen W; Zhang W; Xu J; Cheng J; Yuan X; Li Y
Front Public Health; 2022; 10():1087800. PubMed ID: 36711364
[TBL] [Abstract][Full Text] [Related]
57. Effectiveness of BNT162b2 Vaccine against Omicron Variant Infection among Children 5-11 Years of Age, Israel.
Glatman-Freedman A; Hershkovitz Y; Dichtiar R; Rosenberg A; Keinan-Boker L; Bromberg M
Emerg Infect Dis; 2023 Apr; 29(4):771-777. PubMed ID: 36863005
[TBL] [Abstract][Full Text] [Related]
58. Rapid Selection of Sotrovimab Escape Variants in Severe Acute Respiratory Syndrome Coronavirus 2 Omicron-Infected Immunocompromised Patients.
Gliga S; Lübke N; Killer A; Gruell H; Walker A; Dilthey AT; Thielen A; Lohr C; Flaßhove C; Krieg S; Pereira JV; Seraphin TP; Zaufel A; Däumer M; Orth HM; Feldt T; Bode JG; Klein F; Timm J; Luedde T; Jensen BO
Clin Infect Dis; 2023 Feb; 76(3):408-415. PubMed ID: 36189631
[TBL] [Abstract][Full Text] [Related]
59. Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial.
Corominas J; Garriga C; Prenafeta A; Moros A; Cañete M; Barreiro A; González-González L; Madrenas L; Güell I; Clotet B; Izquierdo-Useros N; Raïch-Regué D; Gallemí M; Blanco J; Pradenas E; Trinité B; Prado JG; Blanch-Lombarte O; Pérez-Caballero R; Plana M; Esteban I; Pastor-Quiñones C; Núñez-Costa X; Taleb RA; McSkimming P; Soriano A; Nava J; Anagua JO; Ramos R; Lluch RM; Comes AC; Romero SO; Gomez XM; Sans-Pola C; Moltó J; Benet S; Bailón L; Arribas JR; Borobia AM; Parada JQ; Navarro-Pérez J; Forner Giner MJ; Lucas RO; Jiménez MDMV; Compán SO; Alvarez-Mon M; Troncoso D; Arana-Arri E; Meijide S; Imaz-Ayo N; García PM; de la Villa Martínez S; Fernández SR; Prat T; Torroella È; Ferrer L
Lancet Reg Health Eur; 2023 May; 28():100613. PubMed ID: 37131861
[TBL] [Abstract][Full Text] [Related]
60. Persistence of Immune Response Elicited by Three Doses of mRNA Vaccine against SARS-CoV-2 in a Cohort of Patients with Solid Tumors: A One-Year Follow-Up.
Lasagna A; Cassaniti I; Arena F; Bergami F; Percivalle E; Comolli G; Sarasini A; Ferrari A; Cicognini D; Schiavo R; Lo Cascio G; Pedrazzoli P; Baldanti F
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]